Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasms 2Sarcoma 1Lymphoma, B-Cell, Marginal Zone 1Carcinoma, Ductal, Breast 1

Interventions

Rituximab 30Cyclophosphamide 18fludarabine phosphate 14Filgrastim 12Mycophenolic Acid 11Antilymphocyte Serum 11Cyclosporine 10Whole-Body Irradiation 9Bortezomib 9Tacrolimus 8Radiotherapy 8Peripheral Blood Stem Cell Transplantation 8Methotrexate 6Lenalidomide 6Cord Blood Stem Cell Transplantation 6Busulfan 6Granulocyte Colony-Stimulating Factor 5venetoclax 4tanespimycin 4Polymerase Chain Reaction 4Methylprednisolone 4Melphalan 4Flow Cytometry 4Etoposide 4Bendamustine Hydrochloride 4ublituximab 3thymoglobulin 3pembrolizumab 3ibritumomab tiuxetan 3fludarabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, B-Cell, Marginal Zone × Pharmaceutical Preparations × Clear all
NCT00210392 2015-03-30

VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy

International Extranodal Lymphoma Study Group (IELSG)

Phase 2 Terminated
12 enrolled
Lymphoid

Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡